Clinical trials: Crystal Arthropathies
Acute Gout Flare, Gout Attack
Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare
The purpose of this trial is to investigate the efficacy and safety of dapansutrile (OLT1177®) tablets in subjects with an acute gout flare.
- Conditions
- Acute Gout Flare, Gout Attack, Gout Flare, Gouty Arthritis
- Trial name
- NCT05658575
- Testing
- Dapansutrile
- Where
- 40 sites in United States, France and 3 more
- Volunteers
- 300 people
- Sponsor
- Olatec Therapeutics, Inc.
Intercritical Gout
PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1
The purpose of this clinical research study was to determine the safety and effectiveness of an experimental drug called rilonacept in subjects with gout who are beginning allopurinol treatment for gout.
- Trial name
- PRE-SURGE1 (NCT00829829)
- Testing
- Rilonacept 80 mg, Rilonacept 160 mg
- Where
- 91 sites in United States, Canada
- Volunteers
- 241 people
- Sponsor
- Regeneron Pharmaceuticals
Hyperuricemia, Gout
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of ABP-671 administered orally in subjects with hyperuricemia.
- Trial name
- NCT04060173
- Testing
- ABP-671
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Atom Therapeutics Co., Ltd
Gout
Intensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With Gout
There is a mounting and clear association between hyperuricaemia, gout and the presence of traditional cardiovascular (CV) risk factors and CV event-equivalent conditions such as chronic kidney disease, metabolic syndrome, and…
- Trial name
- FORWARD (NCT02500641)
- Testing
- Febuxostat 80/120mg/day, Allopurinol 100 up to 600mg/day, Colchicine
- Where
- 26 sites in Germany, Italy and 4 more
- Volunteers
- 196 people
- Sponsor
- Menarini International Operations Luxembourg SA
Gout, Hyperuricemia
Relative Bioavailability Study to Assess an LC350189 Tablet Compared to an LC350189 Capsule in Healthy Adults
This is an open-label, randomized, crossover, single dose study. Two single doses of LC350189(tablet or capsule formulations) will be administered with a washout period of at least 4-day between the doses to investigate the…
- Trial name
- NCT04886050
- Testing
- LC350189 Tablet, LC350189 Capsule
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- LG Chem
Gout
RDEA3170 and Febuxostat Combination Study in Gout Subjects
This is a Phase 2a, randomized, open-label, multicenter study to assess the pharmacodynamic (PD) effects and safety of RDEA3170 administered in combination with febuxostat compared to febuxostat administered alone in adult…
- Trial name
- NCT02246673
- Testing
- RDEA3170 15 mg, RDEA3170 10 mg, RDEA3170 2.5
- Where
- 6 sites in United States
- Volunteers
- 64 people
- Sponsor
- Ardea Biosciences, Inc.
Gout
A Study to Determine the Safety, Tolerability, PK and Preliminary PD of SSS11 in Chinese Healthy Adult Volunteers
To evaluate the safety, tolerability, PK and preliminary PD of SSS11 for injection in chinese healthy adult volunteers.
- Trial name
- NCT04047394
- Testing
- PEGylated recombinant candida urate oxidase
- Where
- China
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Gout Arthritis
A Study of SSGJ-613 in Gout Participants Initiating Urate-Lowering Treatment
The purpose of this study is to determine the efficacy and safety of recombinant anti-interleukin-1β humanized monoclonal antibody injection in Chinese gout participants Initiating Urate-Lowering Treatment
- Trial name
- NCT07708181
- Testing
- SSGJ-613 100 mg Q12W, SSGJ-613 200 mg Q12W, SSGJ-613 100 mg Q4W
- Volunteers
- 200 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Gout Arthritis, Gout Attack
Efficacy Anda Safety of Etoricoxib With Betamethasone for the Treatment of Acute Gout Arthritis
Phase III longitudinal, multicenter, randomized, double-blind clinical trial. The aim of this study is to evaluate the efficacy and safety of the Fixed-Dose Combination of Etoricoxib/Betamethasone Versus Etoricoxib in Patients…
- Trial name
- NCT06863701
- Testing
- Etoricoxib + Betamethasone fixed dose, Etoricoxib fixed dose
- Where
- Mexico
- Volunteers
- 72 people
- Sponsor
- Laboratorios Silanes S.A. de C.V.
Gout
Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic Gout
This is an open-label extension phase of two double-blind, placebo-controled Phase 3 protocols evaluating PEG-uricase in the treatment of hyperuricemic subjects with symptomatic gout.
- Trial name
- NCT01356498
- Testing
- pegloticase
- Where
- 22 sites in United States
- Volunteers
- 151 people
- Sponsor
- Savient Pharmaceuticals
Gout
Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout
D-0120 is being tested in combination with Allopurinol in adult subjects with Gout.
- Trial name
- NCT05665699
- Testing
- D-0120, Allopurinol
- Where
- 19 sites in United States
- Volunteers
- 80 people
- Sponsor
- InventisBio Co., Ltd
Gout and Hyperuricemia
Clinical Trial of BR2251 Tablets for Patients With Primary Gout and Hyperuricemia
This study is a randomized, double-blind, non-befloxacin-controlled, multicenter, phase II clinical trial, evaluating the efficacy, safety, and pharmacokinetic characteristics of BR2251 tablets when administered multiple times in…
- Trial name
- BR2251-201 (NCT07498647)
- Testing
- BR2251, Febuxostat
- Volunteers
- 160 people
- Sponsor
- BioRay Pharmaceutical Co., Ltd.
Gout, Hyperuricemia
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of ABP-671 in Patients With Gout or Hyperuricemia
This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy, safety, and pharmacokinetics study of 6 different dose regimens of ABP-671 compared with placebo.
- Trial name
- NCT04638543
- Testing
- ABP-671
- Where
- 5 sites in Australia
- Volunteers
- 60 people
- Sponsor
- Atom Therapeutics Co., Ltd
Gout Chronic, Gout
Drug-Drug Interaction Study of ABP-671 in Gout Patients
This is a open-Label, Within-Subject Drug-Drug Interaction Study of ABP-671 Added to Stable Allopurinol Therapy in Gout Patients.
- Conditions
- Gout Chronic, Gout, DDI (Drug-Drug Interaction)
- Trial name
- NCT07367971
- Testing
- ABP-671 plus allopurinol
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Atom Therapeutics Co., Ltd
Gout
Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout
These are two replicate studies to evaluate the safety and efficacy of PEG (polyethylene glycol)-uricase in controlling the uric acid level in symptomatic gout patients with high uric acid levels who are unable to take standard…
- Trial name
- NCT00325195
- Testing
- pegloticase
- Where
- 56 sites in United States, Canada and 1 more
- Volunteers
- 225 people
- Sponsor
- Savient Pharmaceuticals
Gout, Hyperuricemia
A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia
The aim of this 12-week randomized multicenter double-blind parallel group placebo-controlled dose finding study is to assess the efficacy and safety of three different doses of LC350189 in subjects with hyperuricemia and a…
- Trial name
- NCT03934099
- Testing
- LC350189 formulated capsule
- Where
- 34 sites in United States
- Volunteers
- 156 people
- Sponsor
- LG Chem
Osteoarthritis of the Shoulder, Avascular Necrosis
Database Retrieval for the Comprehensive Shoulder
This study is a retrieval of database information regarding survivorship of the Comprehensive Shoulder System family of products.
- Conditions
- Osteoarthritis of the Shoulder, Avascular Necrosis, Rheumatoid Arthritis, Prior Failed Revision
- Trial name
- NCT03409718
- Testing
- Biomet Comprehensive Shoulder System
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Zimmer Biomet
Gout
D-0120 Safety and PK/PD, Food Effect Study in Healthy Volunteers
This initial clinical study in the US will be a randomized, double-blind, placebo-controlled, single-dose, dose-escalation, and sequential cohort study to evaluate the safety, tolerability, PK and PD of D-0120-NA in fasting…
- Trial name
- NCT03291782
- Testing
- D-0120
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- InventisBio Co., Ltd
Rotator Cuff Tear Arthropathy, Osteoporosis
COMPREHENSIVE® REVERSE SHOULDER Mini BasePlate
Evaluate Survivorship for the Biomet® Comprehensive® Reverse Shoulder Mini Baseplate.
- Conditions
- Rotator Cuff Tear Arthropathy, Osteoporosis, Osteomalacia, Joint; Destruction, Sacroiliac
- Trial name
- NCT02084693
- Testing
- COMPREHENSIVE
- Where
- 5 sites in South Korea
- Volunteers
- 100 people
- Sponsor
- Zimmer Biomet
Gout, Hyperuricemia
Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients
The aim of this 6-month randomized multi-regional double-blind parallel group placebo-controlled phase 3 study is to assess the efficacy and safety of three different doses of Tigulixostat in gout patients with hyperuricemia.
- Conditions
- Gout, Hyperuricemia, Gout Flare, Tophi
- Trial name
- EURELIA1 (NCT05586958)
- Testing
- Tigulixostat
- Where
- 52 sites in United States, Georgia and 2 more
- Volunteers
- 354 people
- Sponsor
- LG Chem